<DOC>
	<DOCNO>NCT02425826</DOCNO>
	<brief_summary>This study evaluate clinical efficacy , patient quality life , satisfaction , safety oral apremilast 30 mg twice daily ( BID ) compare placebo , subject moderate plaque psoriasis 16 week Placebo control Phase upto 1 year Extension Phase trial .</brief_summary>
	<brief_title>A Phase 4 Study Efficacy Safety Apremilast Subjects With Moderate Plaque Psoriasis .</brief_title>
	<detailed_description>This Phase 4 , multicenter , randomize , placebo-controlled , double-blind study efficacy safety apremilast subject moderate plaque psoriasis . Approximately 219 subject randomize 2 ( apremilast ) :1 ( placebo ) approximately 25 site United States . Subjects randomize apremilast treatment group receive apremilast 30 mg tablet orally twice daily 52 week . Subjects randomize placebo treatment group receive placebo tablet ( identical appearance apremilast 30 mg tablet ) orally twice daily 16 week . Beginning Week 16 , subject initially randomize placebo switch receive apremilast 30 mg BID additional 36 week ( 52 week total ) . Study enroll adult patient stable moderate plaque psoriasis , naïve systemic psoriasis treatment . The primary efficacy endpoint assess Week 16 mean percentage change baseline product body surface area ( BSA ) ( % ) static Physician 's Global Assessment ( sPGA ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Parapsoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Males female , ≥ 18 year age time sign informed consent document . 2 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Diagnosis chronic plaque psoriasis least 6 month prior sign inform consent . 5 . Have moderate plaque psoriasis screen baseline define 1 . BSA ( Body Surface Area ) 5 % 10 % 2. sPGA ( Physician 's Global Assessment ) 3 ( moderate ) base 0 5 point scale 6 . Must general good health ( except psoriasis ) judge investigator , base medical history , physical examination , clinical laboratory . 7 . No prior exposure systemic treatment biologics treatment psoriatic arthritis , psoriasis , indication could impact assessment psoriasis . 8 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . While investigational product least 28 day take last dose investigational product , FCBP engage activity conception possible must use one approve contraceptive§ option describe : Option 1 : Any one follow highly effective method : hormonal contraception ( oral , injection , implant , transdermal patch , vaginal ring ) ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; OR Option 2 : Male female condom ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) PLUS one additional barrier method : ( ) diaphragm spermicide ; ( b ) cervical cap spermicide ; ( c ) contraceptive sponge spermicide . 9 . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception ( male latex condom nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) investigational product least 28 day last dose investigational product 1 . Other psoriasis , clinically significant ( determined Investigator ) cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic disease , major disease currently uncontrolled . 2 . Any condition , include presence laboratory abnormality , would place subject unacceptable risk he/she participate study . 3 . Any condition , include inflammatory disease dermatologic condition , confound ability interpret data study , include type psoriasis ( ie , erythrodermic , guttate , inverse , pustular psoriasis ) , plaque psoriasis . 4 . Prior history suicide attempt time subject 's life time prior signing inform consent randomization , major psychiatric illness require hospitalization within last 3 year prior sign inform consent . 5 . Pregnant breast feeding . 6 . Active substance abuse history substance abuse within 6 month prior sign inform consent . 7 . Malignancy history malignancy , except : 1. treat ( ie , cure ) basal cell squamous cell situ skin carcinoma ; 2. treat ( ie , cure ) cervical intraepithelial neoplasia ( CIN ) carcinoma situ cervix evidence recurrence within 5 year sign informed consent . 8 . Topical therapy within 2 week randomization ( include , limited , topical corticosteroid , retinoids vitamin D analog preparation , tacrolimus , pimecrolimus , anthralin/dithranol ) . Use phototherapy within 4 week prior randomization . 9 . Use investigational drug within 4 week prior randomization , 5 pharmacokinetic/pharmacodynamic halflives , know ( whichever longer ) . 10 . Prolonged sun exposure use tan booth , may confound ability interpret data study . 11 . Prior treatment apremilast .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Parapsoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>CC-10004</keyword>
	<keyword>Apremilast</keyword>
	<keyword>Moderate Plaque Psoriasis</keyword>
	<keyword>Safety</keyword>
</DOC>